KR20020038431A - V - eye clean - Google Patents

V - eye clean Download PDF

Info

Publication number
KR20020038431A
KR20020038431A KR1020000068661A KR20000068661A KR20020038431A KR 20020038431 A KR20020038431 A KR 20020038431A KR 1020000068661 A KR1020000068661 A KR 1020000068661A KR 20000068661 A KR20000068661 A KR 20000068661A KR 20020038431 A KR20020038431 A KR 20020038431A
Authority
KR
South Korea
Prior art keywords
salt
molten
mixture
bamboo
kelp
Prior art date
Application number
KR1020000068661A
Other languages
Korean (ko)
Inventor
김만순
Original Assignee
김만순
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 김만순 filed Critical 김만순
Priority to KR1020000068661A priority Critical patent/KR20020038431A/en
Publication of KR20020038431A publication Critical patent/KR20020038431A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/074—Ganoderma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

PURPOSE: An eye lotion obtained by extracting vegetables, seaweeds, mushrooms or the like and mixing purified salt is provided which is effective for the remedy and prevention of eye diseases such as acute and chronic conjunctivitis. CONSTITUTION: A specified amount of salt is heated at high temperature and mixed with a mixture of oak leaves, kelp, sweet potato leaves, Ganoderma lucidum, Lentinus edodes and bamboo in a ratio of 96:4. The mixture is heated at 1,100 to 1,400deg.C to produce a melted solution. The above procedure is repeated at least 6 times to produce a final product and 0.1% by weight of the product is mixed with 1,000ml purified water.

Description

브이 아이 크린 {V - eye clean}V eye clean {V-eye clean}

본 발명은 천일염, 떡갈잎, 다시마, 고구마잎, 영지버섯, 표고버섯, 대나무로부터 제조한 용융염을 정제수에 용해하여 안구 결막염증을 치료하는 효과와 안압을 정상으로 조절효과를 주는 것과 관련된 것이다.The present invention relates to dissolving molten salt prepared from sun salt, oak leaf, kelp, sweet potato leaf, ganoderma lucidum mushroom, shiitake mushroom, and bamboo in purified water and regulating intraocular pressure and normal intraocular pressure.

특히 본발명은 천일염과 떡갈잎, 다시마, 고구마잎, 영지버섯, 표고버섯, 대나무의 회분을 이용하여 제조한 용융염으로서 급성 결막염, 녹내장, 백내장, 안압과 같은 염증을 치료하는 것과 관련된 것이다. 더욱이 본 발명은 천일염, 떡갈잎, 다시마, 고구마잎, 영지버섯, 표고버섯, 대나무로부터 얻은 염을 인간의 결막염증을 치료하기 위하여 1일 1회 2~3방울 5-6회 눈에 점안하는 방법이다.In particular, the present invention is a molten salt prepared using the sun salt and oak leaf, kelp, sweet potato leaf, ganoderma lucidum mushroom, shiitake mushroom, bamboo ash, and related to treating inflammation such as acute conjunctivitis, glaucoma, cataract and intraocular pressure. Furthermore, the present invention is a method of instilling salts obtained from sun salt, oak leaf, kelp, sweet potato leaf, ganoderma lucidum mushroom, shiitake mushroom, and bamboo in the eye 2 to 3 drops 5-6 times daily to treat conjunctivitis in humans. .

염화나트륨 염으로서 미세한 입자염, 식탁염, 증발염 등이 있으며 용융염을 인간의 눈에 점안하여 결막염증을 치료하는 방법에 대하여는 알려져 있지 않다.Sodium chloride salts include fine particle salts, table salts, and evaporation salts, and there is no known method for treating conjunctivitis by applying molten salts to the human eye.

본 발명은 다음의 자세한 설명에 따라서 충분히 이해될 것이며 관련 도면에 대하여는 간단한 설명을 할 것이지만 그런 것이 본 발명의 한계를 나타내는 것은 아니다.The invention will be fully understood in accordance with the following detailed description and will be briefly described in relation to the accompanying drawings, which are not indicative of the limitations of the invention.

그림 1 : 가공전의 천일염 확대 그림Figure 1: Enlarged picture of sun salt before processing

그림 2 : 본 발명의 3단계 처리에서 형성된 회화염의 확대 그림Figure 2: Magnified illustration of antifoam salt formed in the three step treatment of the present invention

그림 3 : 본 발명의 4단계 처리에서 형성된 고화염의 확대 그림Figure 3: Magnified Picture of Solid Flame Formed in a Four-Step Treatment of the Present Invention

그림 4 : 본 발명의 5단계 처리에서 형성된 고화염의 확대 그림Figure 4: Magnified Picture of Solid Flame Formed in a Five-Step Treatment of the Present Invention

그림 5 : 본 발명의 염과 비교하기 위하여 천일염을 1,000~1,100℃에서 용융한 염의 확대 그림Figure 5: Magnified picture of salts melted at 1,000-1,100 ° C for natural salts to compare with salts of the present invention

그림 6 : 본 발명에서 사용한 가열로의 조감도Figure 6: Bird's eye view of the furnace used in the present invention

그림 7 : 본 발명의 용융염을 채운 대나무 다발을 세운 가열로의 조감도Figure 7: Aerial view of a furnace with bamboo bundles filled with molten salt of the present invention

그림 8 : 고형염 막대를 세워 놓은 판넬의 조감도Figure 8: Bird's eye view of the panel on which the solid salt rods are erected

본 발명과 그림에 대한 상세한 설명은 의약적 식품에 사용하기 위한 염 조성에 대하여 마련한다. 본 발명의 의약적 식품염 조성은 천일염, 떡갈잎, 다시마, 고구마잎, 영지버섯, 표고버섯 및 대나무와 같은 자연 원료로부터 제조된다.처음의 그림 1 에 표시한 것과 같은 가공하지 않은 천일염을 그림 6 에 표시한 가열로 10의 연소 콘테이너 11에서 약 500~700℃로 가열해서 증발염 분말을 생성한다. 가열하는 동안 3M의 문 14, 15, 16은 닫는다.Detailed description of the invention and the drawings provides for salt compositions for use in medicinal foods. The pharmaceutical food salt composition of the present invention is prepared from natural raw materials such as sun salt, oak leaf, kelp, sweet potato leaf, ganoderma lucidum mushroom, shiitake mushroom and bamboo. The evaporation salt powder is produced by heating to about 500-700 degreeC in the combustion container 11 of the indicated furnace 10. 3M's doors 14, 15 and 16 are closed during heating.

증발염 분말은 가열할 때에 자연 원료화 결합해서 초기의 혼합물을 형성한다. 자연 원료인 떡갈잎, 다시마, 고구마잎, 표고버섯, 영지버섯 및 대나무를 자르고 220 메슈로 분쇄한 것이다.The evaporated salt powder combines with natural raw materials when heated to form an initial mixture. Natural raw materials oak leaf, kelp, sweet potato leaf, shiitake mushroom, ganoderma lucidum mushroom and bamboo were cut and crushed into 220 meshes.

이를 원료는 중량비로 등량 혼합한 것이다. 떡갈잎, 다시마, 고구마잎, 표고버섯, 영지버섯, 대나무와 결합할 용융염 분말의 양은 원료의 양 6%에 대하여 94%이다.The raw materials are mixed in equal proportions by weight. The amount of molten salt powder to be combined with oak leaf, kelp, sweet potato leaf, shiitake mushroom, ganoderma lucidum mushroom and bamboo is 94% based on 6% of the amount of raw material.

실예로서 20kg의 용윰염에 대하여 1000g의 자연 원료를 혼합하여 초기 혼합물이 되는 것이다.As an example, 1000 g of natural raw materials are mixed with 20 kg of molten salt to form an initial mixture.

제 2 단계에 있어서 그림 6에서 표시한 바와 같이 초기 혼합물은 연소가 있는 아궁이 12에서 태운다. 연소 콘테이너 11은 그바닥에 전면, 뒤, 좌측문 14, 15 및 16과 좌측벽 13에 용액 배출구 17로 되어있다. 이때에 앞과 뒷문 14와 15는 닫고 좌측문 16은 열어 놓는다. 장작이 측벽 13에 용액 배출구 17로 되어있다.In the second stage, as shown in Figure 6, the initial mixture is burned at 12, with burning fire. The combustion container 11 has a front, rear, left door 14, 15 and 16 at its bottom and a solution outlet 17 at the left wall 13. At this time, the front and rear doors 14 and 15 are closed and the left door 16 is open. Firewood has a solution outlet 17 on the side wall 13.

이때에 앞과 뒷문 14와 15는 닫고 좌측문 16은 열어 놓는다. 장작이 공기 유입구 18로 들어온 신선한 공기와 연소하게 되며 물길은 터널 19를 통하여 굴뚝 20으로 나간다.At this time, the front and rear doors 14 and 15 are closed and the left door 16 is open. The firewood burns with fresh air entering air inlet 18 and the waterway exits chimney 20 through tunnel 19.

이때에 앞과 뒷문 14와 15는 닫고 좌측문 16은 열어 놓는다. 장작이 공기 유입구 18로 들어온 신선한 공기와 연소하게 되며 불길은 터널 19를 통하여 굴뚝 20으로 나간다.At this time, the front and rear doors 14 and 15 are closed and the left door 16 is open. The firewood burns with fresh air entering the air inlet 18 and the flame exits through the tunnel 19 to the chimney 20.

이때에 초기 혼합물의 온도는 약 1,100~1,400℃이며 자연 원료인 유황, 카리움 등과 같은 자연 미네랄은 초기 원료와 결합해서 용융 용액이 되어 용액 배출구 17로 배출되며 소량의 용융은 굴뚝 20을 통하여 증발된다. 용액 배출구 17로부터 나온 용융 용액은 즉시 고화되어 흑회색의 용융염으로 된다.At this time, the temperature of the initial mixture is about 1,100 ~ 1,400 ℃, and natural minerals such as sulfur and carium, which are natural raw materials, are combined with the initial raw materials to form a molten solution and are discharged to the solution outlet 17. A small amount of melt is evaporated through the chimney 20 . The molten solution from solution outlet 17 immediately solidifies to a black gray molten salt.

제 3 단계에서는 흑회색의 고체 용융염을 일반 분쇄기로 분체해서 분말화 한다. 제 1 단계에서 사용했던 것과 같은 자연 원료 분말을 염분말에 첨가한다. 진술한 바와 같이 본 발명의 2 단계 연소 공정을 되풀이 한다. 본 방법의 3 단계를 5-6회 반복해서 다량 미네랄을 함유한 최종 분말 제품을 얻는다.In the third step, the black gray solid molten salt is powdered by using an ordinary mill. The natural raw powder as used in the first step is added to the salt powder. As stated, the two stage combustion process of the present invention is repeated. Repeat step 3 of this process 5-6 times to obtain a final powder product containing a large amount of minerals.

제 4 단계에서는 3 단계에서 얻은 분말 24를 대나무통 22에 넣고 그림 7에 표시한 바와 같이 회화로 10에 있는 연소로 11에 다발로 세워 놓는다. 이때에 장작으로 연소시켜 염 막대를 얻게 된다. 이 과정에서 그림 8에 표시한 바와 같이 연소로 10의 연소 콘테이너 11에서 고체염 막대가 형성된다.In the fourth step, the powder 24 obtained in step 3 is placed in the bamboo barrel 22 and bunched up in the furnace 11 in the incineration furnace 10 as shown in Figure 7. At this time, firewood is burned to obtain a salt bar. In this process, solid salt rods are formed in the combustion container 11 of the furnace 10 as shown in Figure 8.

제 5 단계에서는 고체염 다발 24를 연소로 10의 연소 콘테이너 11에 넣고 1,100~1,400℃로 가열해서 용융시키고 용액 배출구 17을 통해서 배출시킨다. 배출된 용융 용액은 대기 중에서 흑회색의 고체 용융염으로 된다.In the fifth step, the bundle of solid salt 24 is placed in the combustion container 11 of the combustion furnace 10, heated to 1,100 to 1,400 ° C. to be melted, and discharged through the solution outlet 17. The discharged molten solution becomes black gray solid molten salt in the atmosphere.

제 6 단계에서는 용융 고체 제품을 전기로에 넣고 500℃~800℃로 가열하면 용융이 시작된다. 그 다음에 온도를 1,400℃까지 올려서 고체제품에 함유되어 있는 불순물을 완전히 태워서 정제 제품을 얻는다. 가공되지 않은 천일염은 본 발명의 제품과 비교할 때 현저히 높은 온도인 1,000℃에서 용융이 시작된다.In the sixth step, the molten solid product is placed in an electric furnace and heated to 500 ° C. to 800 ° C. to start melting. The temperature is then raised to 1,400 ° C. to completely burn off the impurities contained in the solid product to obtain a purified product. Raw natural salts begin to melt at 1,000 ° C., which is a significantly higher temperature compared to the products of the present invention.

이와 같은 사실은 본 발명의 제품과 일반 천일염과의 차이를 나타내는 것이다.This fact is indicative of the difference between the product of the present invention and general sun salt.

A. 시점 예 1 : 눈 결막염의 치료A. Point Example 1: Treatment of eye conjunctivitis

M.S.G 는 48세 부인과 53세의 남자는 만성 결막염과 망막염을 앓고 있었다. 위의 두 사람은 18년간 만성 결막염과 만성 망막염으로 시력이 저하되어 생활에 큰 불편을 겪었으며 때로는 안압 상승으로 녹내장이 생기기 시작하였다 이러한 증세는신경을 많이 쓰거나 스트레스를 많이 받으면 더욱 증세가 심하였습니다. 남녀 두 사람은 9일간 3단계로 나누어 3일간의 간격을 두고 1일 2~3방울씩 5~6회 점안 하였으며 치료기간 중에는 전혀 부작용이 없었으며 신경과 관련한 독성은 전혀 보고된 바 없으며, 환자였던 남녀 두 사람은 안압도 정상으로 유지되었으며 결막염증도 핏발이 사라지면서 완치가 되었으며 시력도 정상으로 회복되었다.M.S.G had a 48-year-old wife and a 53-year-old man with chronic conjunctivitis and retinitis. The above two people suffered from vision loss due to chronic conjunctivitis and chronic retinitis for 18 years, and often caused glaucoma due to increased intraocular pressure. These symptoms were more severe when a lot of nerves or stress were used. Two men and women were divided into three phases of nine days, with three to five drops of eye drops, three to three days apart, with no side effects during the treatment period, and no neurotoxic toxicity was reported. Both men and women had normal intraocular pressure, conjunctivitis cure as the blood disappeared, and vision returned to normal.

B. 제품 예 1 : 용액B. Product Example 1: Solution

순수하게 정제된 제품에 정제수 1,000㎖에 용융염 0.12%를 용해시켜 10㎖ 용량 병에 넣어 1일 1회 2~3방울 5~6회 눈에 점안할 수 있다.Dissolved 0.12% of molten salt in 1,000 ml of purified water in a purely purified product, and put it in a 10 ml volume bottle.

표 1 에 표시한 결과는 본 발명에 따라서 가공된 용윰염을 한국 화학시험연구원에 의해서 분석한 것이다. 기술한 바와 같은 본 발명은 같은 것이 여러 방법에 따라서 다르게 나타날 수 있다.The results shown in Table 1 are the analysis of the molten salt processed according to the present invention by the Korea Institute of Chemical Testing. The present invention as described may appear differently according to several methods.

그러한 차이는 본 발명의 정신이나 범위에서 벗어나는 것은 아니고 모든 그러한 변형은 다음의 청구 범위에 속하는 것이 확실하다.It is apparent that such differences do not depart from the spirit or scope of the present invention and all such modifications fall within the scope of the following claims.

본 발명은 용융염에서 얻게 되는 안구 염증치료 성분이 함유되었고 이 용융염을 안약 치료약으로 사용된다.The present invention contains an eye inflammation treatment component obtained from molten salt, and the molten salt is used as an ophthalmic treatment drug.

본 발명은 또한 급성 및 만성 결막염 치료제 약으로 사용된다.The invention is also used as a drug for treating acute and chronic conjunctivitis.

Claims (3)

인간에게 발생되는 염증을 치료하기 위한 약리적 항 염증 성분은 약학적으로 적합하며 항 염증효과가 있는 용융염으로서 다음 단계가 포함된다.Pharmacological anti-inflammatory components for treating inflammation occurring in humans are pharmaceutically suitable and anti-inflammatory molten salts and include the following steps. (a) 미리 정량한 염의 일정량을 고온에서 가열하여 염 분말을 형성하는 것(a) heating a predetermined amount of a predetermined quantity of salt at high temperature to form salt powder (b) 진술한 염 분말과 떡갈잎, 다시마, 고구마잎, 영지버섯, 표고버섯 대나무를 혼합하여 초기 혼합물을 만들고 염과 혼합물의 비율을 중량비로 96% : 5%로 하는 것(b) Mix the stated salt powder with oak leaf, kelp, sweet potato leaf, ganoderma lucidum mushroom and shiitake bamboo to make an initial mixture, and the ratio of salt to mixture is 96% to 5% by weight. (c) 초기 혼합물은 장작을 떼서 온도를 1,100~1,400℃로 한 연소로에서 연소함으로써 첫번째 용융 용액을 만들며 이를 고화해서 첫번째 용융 고체염을 형성하는 것(c) The initial mixture is fired in a combustor at a temperature of 1,100 to 1,400 ° C with firewood removed to form the first molten solution which solidifies to form the first molten solid salt. (d) 용융 고체염을 분해해서 분말 고체로 만드는 것(d) decomposing molten solid salts into powder solids (e) 분쇄된 고체염과 떡갈잎, 다시마, 고구마잎, 표고버섯, 영지버섯, 대나무와 혼합해서 연소로에서 장작을 태워 1.100~1,400℃로 하고 제2 용융 고체염을 생성하는 것(e) Mixing with pulverized solid salt, oak leaf, kelp, sweet potato leaf, shiitake mushroom, ganoderma lucidum mushroom and bamboo, burning firewood in the furnace to make 1.100 ~ 1,400 ℃ and to produce second molten solid salt. (f)(d) 및 (e)를 적어도 6회 반복하는 것repeating (f) (d) and (e) at least six times (g)(f)단계에서 형성된 대나무 다발을 태워서 셋째번 용융 용액을 만들고 이를 고하시켜서 용융 고체를 만드는 것(g) burning the bundle of bamboos formed in step (f) to form a third melted solution and beating it to form a molten solid (i)셋째번 용융 고체염은 1,400℃의 전기로에서 가열하여 최종 용융염 혼합물을 형성하는 것(i) The third molten solid salt is heated in an electric furnace at 1,400 ° C. to form the final molten salt mixture. 인간 안구 염증을 치료하기 위하여 떡갈잎, 다시마, 고구마잎, 표고버섯, 영지버섯, 대나무가 혼합된 용융염을 눈의 결막염, 망막염 등에 점안하며, 혼합물의 배합비율은 정제수 1,000㎖ 에 용융염 0.1%로 용해한다.To treat human eye inflammation, apply molten salt mixed with oak leaf, kelp, sweet potato leaf, shiitake mushroom, ganoderma lucidum mushroom, and bamboo to eye conjunctivitis, retinitis, etc.The blending ratio of the mixture is 1,000 ml of purified water and 0.1% molten salt. Dissolve. 청구 범위 2의 방법으로 1일 2~3방울 5~6회 용해된 용융염을 정제수 1,000㎖ 0.1% 를 혼합 용해하여 점안하는 것Applying and dissolving 1,000 ml 0.1% of purified water in the molten salt dissolved 2-3 drops 5-6 times a day by the method of Claim 2
KR1020000068661A 2000-11-17 2000-11-17 V - eye clean KR20020038431A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020000068661A KR20020038431A (en) 2000-11-17 2000-11-17 V - eye clean

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020000068661A KR20020038431A (en) 2000-11-17 2000-11-17 V - eye clean

Publications (1)

Publication Number Publication Date
KR20020038431A true KR20020038431A (en) 2002-05-23

Family

ID=19699822

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020000068661A KR20020038431A (en) 2000-11-17 2000-11-17 V - eye clean

Country Status (1)

Country Link
KR (1) KR20020038431A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020082193A (en) * 2002-10-08 2002-10-30 만 석 박 The medicine for the eyes and manufacturing method of that

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR890004712A (en) * 1987-09-10 1989-05-09 김윤세 Nuclear arsenic-containing bamboo salt and its manufacturing method
KR900001844A (en) * 1988-07-26 1990-02-27 유주현 Cyclodextrin-producing enzymes and their producing microorganisms
KR920017666A (en) * 1991-03-29 1992-10-21 박동안 Preparation of dermatitis and its products
KR940003560A (en) * 1992-08-14 1994-03-12 이용남 Manufacturing method of bamboo salt and its use
KR970005294A (en) * 1996-11-04 1997-02-19 강권중 Eye wash water containing bamboo power and bamboo salt as active ingredients

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR890004712A (en) * 1987-09-10 1989-05-09 김윤세 Nuclear arsenic-containing bamboo salt and its manufacturing method
KR900001844A (en) * 1988-07-26 1990-02-27 유주현 Cyclodextrin-producing enzymes and their producing microorganisms
KR920017666A (en) * 1991-03-29 1992-10-21 박동안 Preparation of dermatitis and its products
KR940003560A (en) * 1992-08-14 1994-03-12 이용남 Manufacturing method of bamboo salt and its use
KR970005294A (en) * 1996-11-04 1997-02-19 강권중 Eye wash water containing bamboo power and bamboo salt as active ingredients

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020082193A (en) * 2002-10-08 2002-10-30 만 석 박 The medicine for the eyes and manufacturing method of that

Similar Documents

Publication Publication Date Title
DE69318033T2 (en) ANTITUARY COMPOSITIONS CONTAINING TAXAN DERIVATIVES
CN101641117A (en) Pharmaceutical composition
DE68912850T2 (en) Activity potentiator against cancer.
DE2751570A1 (en) CARBOXYMETHYLATED BETA-1,3-GLUCANES, METHOD FOR MANUFACTURING THEREOF AND ANTITUMOR AGENTS
EP0553658B2 (en) Pharmaceutically active composition from Tanacetum partenium, process of extraction and medicinal composition
DE4420407A1 (en) Prodn. of moxae for use in Chinese medicine
KR20020038431A (en) V - eye clean
DE2922561A1 (en) METHOD FOR PRODUCING PROTEIN ISOLATES
DE60310742T2 (en) EXTRACT WITH ANTITUMORAL AND ANTITOXIC EFFECT
KR100701471B1 (en) A method for manufacturing bamboo salt
KR900001844B1 (en) Process for preparing hygienic reproducted salts
MXPA04011794A (en) Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone.
US318468A (en) Eye remedy
Lewis The New Dispensatory: Containing: The elements of pharmacy. The materia medica.... The preparations and compositions of the new London and Edinburgh pharmacopœias... the most useful of those directed in the hospitals; sundry elegant extemporaneous forms, &c., digested in such a method as to compose a regular system of pharmacy; with remarks on their preparation and uses; the means of distinguishing adulterations; of performing the more difficult and dangerous processes with ease and safety, &c., the whole interspersed with practical cautions and observations. I.. II.. III.
WO1991001742A1 (en) Biologically active compositions
EP0747034B1 (en) Powder mixture for the preparation of a paste of opaque material
Eberl Ideengeschichte in der Vielfalt der Disziplinen. Anmerkungen aus politikwissenschaftlicher Sicht
DE60037197T2 (en) USE OF FUNCTIONAL ORAL PREPARATIONS
JP4405611B2 (en) Liver damage protective agent
DE3603242C2 (en)
Chatrabhuji et al. A REVIEW ON DIFFERENT METHODS OF POORNA CHANDRODAYA RASA NIRMAANA WSR TO RASA TANTRA SAARA EVAM SIDDHA PRAYOGA SANGRAHA
DE935661C (en) Process for making whole wheat bread
KR950012622B1 (en) Health food containing extract of mushroom
DE2803681A1 (en) NEW POLYSACCARIDES AND METHODS FOR THEIR PRODUCTION
JPH059110A (en) Bathing agent

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application
E601 Decision to refuse application